Print This Story  Email This Story  Save this Link View PR Newswire's RSS Feed  Blogs Discussing this News Release  Search Blogs that Mention this News Release  Click this link to view linked Bookmarking Services Click this link to view linked Blogging Services

Pfizer to Return Indiplon Worldwide Rights to Neurocrine
 
    NEW YORK, June 22 /PRNewswire-FirstCall/ -- Pfizer Inc said today it is
returning to Neurocrine Biosciences, Inc. the development and marketing
rights for Indiplon, a medicine in development to treat insomnia. This
includes both the collaboration to develop and co-market Indiplon in the
U.S. as well as Pfizer's exclusive license to develop and market Indiplon
outside of the U.S.
SOURCE Pfizer Inc



Back to Topback to top

Related links:
  • http://www.pfizer.com
    Photo Notes:A free corporate logo to accompany this
    story is availableimmediately via Wieck Photo Database to any
    media with telephoto receiveror electronic darkroom, PC or
    Macintosh, that can accept overheadtransmissions. To retrieve a
    logo, please call 972-392-0888./ /Company News On-Call:
    http://www.prnewswire.com/comp/688250.html
    Pfizer's press releases are available through PR Newswire's
    Company News On-Call service on PRN's Web Site. Visit
  • http://www.prnewswire.com/comp/688250.html/
    CONTACT:
    Paul Fitzhenry of Pfizer Inc, +1-212-733-4637
    www.technorati.com Blogs Linking to this News Release at Technorati
    Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
    Terms and conditions, including restrictions on redistribution, apply.
    Copyright © 1996- PR Newswire Association LLC. All Rights Reserved.
    A United Business Media company.